de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, Wang TL, Shih IM, Schwartz LE, Kim S, Morgan MA, Tanyi JL, Burns KH, Lengyel E, Parra-Herran C, Godwin AK, Walt DR, Drapkin R LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. , NPJ Precis Oncol: 2025
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. , Nat Med: 2025
Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ. Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations , Int J Surg Pathol: 2024
Li S, Oatman E, Tanyi J, Kim SH, Cory L, Mangalmurti NS. Detection of HPV DNA on Red Blood Cells. , Oral presentation. Mid-Atlantic Gynecologic Oncology Society Conference. Atlanta, GA.: 2024
Tanyi JL, O’Hara M, Hexner E, Marshall A, Jadlowsky J, Farrelly O, Carly Stein C, Anne Chew A, Emily Dowd E, Vanessa Gonzalez V, Joseph Fraietta J, Gabriela Plesa G, Neil Sheppard N, Carl June C. Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer. , Oral Presentation. Advancing Gene and Cell Therapies for Cancer Conference. Philadelphia, PA: 2024
Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study , Ann Surg Oncol: 2024
Pohlmann P R, Abdou Y, Johnson M, Maziarz RT, Specht J, Dees E Claire, Yuan Y, Tanyi J, Angelos M, Gill S, Wetzel J, Cushing D, Klichinsky M, Condamine T, and Reiss K A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. , ASCO Chicago, IL (TIP- Trail in progress): 2024
Simpkins F, Nasioudis D, Wethington S, Martin L. Tanyi, J, Latif N, Torigian D, Omran D, Rodriguez D, Smith S, Dean E, Domchek S, Drapkin R, Shih I, Brown, E, Hwang W, Armstrong D, Gaillard S, Giuntoli R, Liu J Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). , ASCO, 2024, Annual Meeting. Chicago, IL: 2024
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Huang J, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Tavana O, Chan HM, Hu X, Zhang L. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment , bioRxiv
: 2024
Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study , Ann Surg Oncol.: 2024,doi: 10.1245/s10434-024-15307-8. Online ahead of print
